Literature DB >> 30392042

Combined cognitive, psychomotor and electrophysiological biomarkers in major depressive disorder.

Ping Chai Koo1,2, Christoph Berger3, Golo Kronenberg1, Julia Bartz1, Peter Wybitul1, Olaf Reis3, Jacqueline Hoeppner4,5.   

Abstract

The diagnosis of major depressive disorder (MDD) should be based on multimodal evidence, because MDD not only affects mood, but also psychomotor and cognitive functions. Clinical markers such as executive dysfunctions and a reduction in daily motor activity have been observed in MDD. Neurophysiological biomarkers have also been described. In this study, we investigate the utility of combining biomarkers related to executive dysfunctions, motor activity, neurophysiological patterns (i.e. alpha power asymmetry and EEG-vigilance as indicators of brain arousal), and the interaction of these parameters in the diagnosis of MDD. Twenty (female: 11) patients with MDD (age: 51.05 ± 10.50) and 20 (female: 13) healthy controls (HC; age: 47.15 ± 12.57) underwent a 10-min resting EEG. Executive dysfunctions were assessed using the Trail Making Test B (TMT B). Motor activity was analysed by actigraphy measurements. MDD patients displayed significant impairments in executive functions and reduced daily motor activity. In the EEG, MDD patients showed more right than left frontal activity and lower brain arousal relative to HC. TMT B and asymmetrical frontal alpha power alone discriminated between MDD patients and HC with an accuracy of 78%. The interaction of motor activity and the EEG-vigilance stage alongside TMT B increased the accuracy of the discrimination test to 81%. This improved accuracy suggests that the combination of these biomarkers in a discriminant analysis resulted in a more reliable identification of MDD patients.

Entities:  

Keywords:  Actigraphy; Biomarkers; EEG; Executive dysfunction; Major depressive disorder

Mesh:

Substances:

Year:  2018        PMID: 30392042     DOI: 10.1007/s00406-018-0952-9

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  5 in total

1.  Mood, psychomotor, and cognitive function in major depressive disorder: from biomarkers to rapid-acting antidepressants.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-10       Impact factor: 5.270

Review 2.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 3.  Cognitive Impairment and Neurocognitive Profiles in Major Depression-A Clinical Perspective.

Authors:  Åsa Hammar; Eivind Haga Ronold; Guro Årdal Rekkedal
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

4.  Anxiolytic Effect of Carvedilol in Chronic Unpredictable Stress Model.

Authors:  Caren Nádia Soares de Sousa; Ingridy da Silva Medeiros; Germana Silva Vasconcelos; Gabriel Ângelo de Aquino; Francisco Maurício Sales Cysne Filho; Jamily Cunha de Almeida; Ana Paula Negreiros Nunes Alves; Danielle S Macêdo; Luzia Kalyne Almeida Moreira Leal; Silvânia Maria Mendes Vasconcelos
Journal:  Oxid Med Cell Longev       Date:  2022-08-19       Impact factor: 7.310

5.  Potential biomarkers of major depression diagnosis and chronicity.

Authors:  Ana Cecília de Menezes Galvão; Raíssa Nobrega Almeida; Geovan Menezes de Sousa Júnior; Mário André Leocadio-Miguel; Fernanda Palhano-Fontes; Dráulio Barros de Araujo; Bruno Lobão-Soares; João Paulo Maia-de-Oliveira; Emerson Arcoverde Nunes; Jaime Eduardo Cecilio Hallak; Jerome Sarris; Nicole Leite Galvão-Coelho
Journal:  PLoS One       Date:  2021-09-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.